Cytrx cancer drug shows promise in mid-stage study

LadRx

06/01/2015 11:31

Jan 6 (Reuters) - Cytrx Corp  CYTR.O  said interim data 
showed its experimental cancer drug was effective in a mid-stage 
study to treat patients with a deadly form of brain cancer. 
    The drug, aldoxorubicin, prevented the disease from 
progressing and shrank tumors, the company said.  ID:nPn7J7x8f  
    The U.S. Food and Drug Administration had placed a hold on 
enrolling new patients in clinical trials of aldoxorubicin in 
November, after a patient died.  ID:nL3N0T84DB  
 
 (Reporting by Rosmi Shaji in Bengaluru; Editing by Savio 
D'Souza) 
 ((Rosmi.Shaji@thomsonreuters.com; Within U.S.+1 646 223 8780 
and outside U.S. +91 8067496753; Reuters Messaging: 
rosmi.shaji.thomsonreuters.com@reuters.net)) 
 
Keywords: CYTRX STUDY/